

# [Genetic profile for patients with DLBCL, 1/14](#)

written by CAP TODAY

January 17, 2014

January 2014—Diagnovus announced an addition to its Engauge cancer assay portfolio with the launch of the Engauge-cancer DLBCL Gene Panel, a genomic profile to aid physicians in tailoring treatment specifically for patients with diffuse large B-cell lymphoma.

The Engauge-cancer DLBCL Gene Panel is a multiplexed, next-generation sequencing-based assay for detecting genomic alterations across numerous hotspots in a patient's DLBCL cancer genome. The panel, which interrogates 17 somatically altered genes, can be performed in a highly reproducible and accurate manner using routinely available formalin-fixed, paraffin-embedded diagnostic biopsy tissue.

[Diagnovus](#), 855-642-8438



©2026 CAP TODAY, all rights reserved.